This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bergman, A. M. Articles by Peters, G. J. Search for Related Content PubMed PubMed Citation Articles by Bergman, A. M. Articles by Peters, G. J.

In vivo Induction of Resistance to Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunit M1 as the Major Determinant

Departments of ¹ Medical Oncology, ² Pediatric Hematology/Oncology, and ³ Microarray Facility, VU University Medical Center, Amsterdam, the Netherlands

Requests for reprints: Godefridus J. Peters, Department of Medical Oncology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. Phone: 20-444-2633; Fax: 20-444-3844; E-mail: gj.peters{at}vumc.nl.

Gemcitabine is a deoxycytidine (dCyd) analogue with activity against several solid cancers. Gemcitabine is activated by dCyd kinase (dCK) and interferes, as its triphosphate dFdCTP, with tumor growth through incorporation into DNA. Alternatively, the metabolite gemcitabine diphosphate (dFdCDP) can interfere with DNA synthesis and thus tumor growth through inhibition of ribonucleotide reductase. Gemcitabine can be inactivated by the enzyme dCyd deaminase (dCDA). In most in vitro models, resistance to gemcitabine was associated with a decreased dCK activity. In all these models, resistance was established using continuous exposure to gemcitabine with increasing concentrations; however, these in vitro models have limited clinical relevance. To develop in vivo resistance to gemcitabine, we treated mice bearing a moderately sensitive tumor Colon 26-A (T/C = 0.25) with a clinically relevant schedule (120 mg/kg every 3 days). By repeated transplant of the most resistant tumor and continuation of gemcitabine treatment for >1 year, the completely resistant tumor Colon 26-G (T/C = 0.96) was created. Initial studies focused on resistance mechanisms known from in vitro studies. In Colon 26-G, dCK activity was 1.7-fold decreased; dCDA and DNA polymerase were not changed; and Colon 26-G accumulated 1.5-fold less dFdCTP, 6 hours after a gemcitabine injection, than the parental tumor. Based on in vitro studies, these relative minor changes were considered insufficient to explain the completely resistant phenotype. Therefore, an expression microarray was done with Colon 26-A versus Colon 26-G. Using independently grown nonresistant and resistant tumors, a striking increase in expression of the RRM1 subunit gene was found in Colon 26-G. The expression of RRM1 mRNA was 25-fold increased in the resistant tumor, as measured by real-time PCR, which was confirmed by Western blotting. In contrast, RRM2 mRNA was 2-fold decreased. However, ribonucleotide reductase enzyme activity was only moderately increased in Colon 26-G. In conclusion, this is the first model with in vivo induced resistance to gemcitabine. In contrast to most in vitro studies, dCK activity was not the most important determinant of gemcitabine resistance. Expression microarray identified RRM1 as the gene with the highest increase in expression in the Colon 26-G, which might clarify its complete gemcitabine-resistant phenotype. This study is the first in vivo evidence for a key role for RRM1 in acquired gemcitabine resistance.

This article has been cited by other articles:

				C. Meischl, H. P. Buermans, T. Hazes, M. J. Zuidwijk, R. J. P. Musters, C. Boer, A. van Lingen, W. S. Simonides, M. A. Blankenstein, C. Dupuy, et al. H9c2 cardiomyoblasts produce thyroid hormone Am J Physiol Cell Physiol, May 1, 2008; 294(5): C1227 - C1233. [Abstract] [Full Text] [PDF]

				G. Bepler Genes Predictive of Chemotherapeutic Efficacy in Non-small Cell Lung Cancer ASCO Educational Book, January 1, 2008; 2008(1): 350 - 352. [Abstract] [Full Text] [PDF]

				L.-Y. Tang, N. Deng, L.-S. Wang, J. Dai, Z.-L. Wang, X.-S. Jiang, S.-J. Li, L. Li, Q.-H. Sheng, D.-Q. Wu, et al. Quantitative Phosphoproteome Profiling of Wnt3a-mediated Signaling Network: Indicating the Involvement of Ribonucleoside-diphosphate Reductase M2 Subunit Phosphorylation at Residue Serine 20 in Canonical Wnt Signal Transduction Mol. Cell. Proteomics, November 1, 2007; 6(11): 1952 - 1967. [Abstract] [Full Text] [PDF]

				J. Wang, G. J. S. Lohman, and J. Stubbe Enhanced subunit interactions with gemcitabine-5'-diphosphate inhibit ribonucleotide reductases PNAS, September 4, 2007; 104(36): 14324 - 14329. [Abstract] [Full Text] [PDF]

				G. Simon, A. Sharma, X. Li, T. Hazelton, F. Walsh, C. Williams, A. Chiappori, E. Haura, T. Tanvetyanon, S. Antonia, et al. Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., July 1, 2007; 25(19): 2741 - 2746. [Abstract] [Full Text] [PDF]

				P. Tooker, W.-C. Yen, S.-C. Ng, A. Negro-Vilar, and T. W. Hermann Bexarotene (LGD1069, Targretin), a Selective Retinoid X Receptor Agonist, Prevents and Reverses Gemcitabine Resistance in NSCLC Cells by Modulating Gene Amplification Cancer Res., May 1, 2007; 67(9): 4425 - 4433. [Abstract] [Full Text] [PDF]

				Z. Zheng, T. Chen, X. Li, E. Haura, A. Sharma, and G. Bepler DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer N. Engl. J. Med., February 22, 2007; 356(8): 800 - 808. [Abstract] [Full Text] [PDF]

				G. Bepler, I. Kusmartseva, S. Sharma, A. Gautam, A. Cantor, A. Sharma, and G. Simon RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non-Small-Cell Lung Cancer J. Clin. Oncol., October 10, 2006; 24(29): 4731 - 4737. [Abstract] [Full Text] [PDF]